CN101219992B - 匹伐他汀钙的晶形 - Google Patents

匹伐他汀钙的晶形 Download PDF

Info

Publication number
CN101219992B
CN101219992B CN2008100012910A CN200810001291A CN101219992B CN 101219992 B CN101219992 B CN 101219992B CN 2008100012910 A CN2008100012910 A CN 2008100012910A CN 200810001291 A CN200810001291 A CN 200810001291A CN 101219992 B CN101219992 B CN 101219992B
Authority
CN
China
Prior art keywords
crystalline state
state form
dihydroxyl
fluorophenyl
quinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2008100012910A
Other languages
English (en)
Chinese (zh)
Other versions
CN101219992A (zh
Inventor
P·A·范德沙夫
F·布拉特
M·谢拉吉维茨
K·-U·舍宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissan Chemical Corp
Original Assignee
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32865094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101219992(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nissan Chemical Corp filed Critical Nissan Chemical Corp
Publication of CN101219992A publication Critical patent/CN101219992A/zh
Application granted granted Critical
Publication of CN101219992B publication Critical patent/CN101219992B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
CN2008100012910A 2003-02-12 2004-02-02 匹伐他汀钙的晶形 Expired - Lifetime CN101219992B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03405080 2003-02-12
EP03405080.7 2003-02-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800039523A Division CN100374422C (zh) 2003-02-12 2004-02-02 匹伐他汀钙的晶形

Publications (2)

Publication Number Publication Date
CN101219992A CN101219992A (zh) 2008-07-16
CN101219992B true CN101219992B (zh) 2011-08-31

Family

ID=32865094

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2008100012910A Expired - Lifetime CN101219992B (zh) 2003-02-12 2004-02-02 匹伐他汀钙的晶形
CNB2004800039523A Expired - Lifetime CN100374422C (zh) 2003-02-12 2004-02-02 匹伐他汀钙的晶形
CN201110189197.4A Expired - Lifetime CN102285916B (zh) 2003-02-12 2004-02-02 匹伐他汀钙的晶形

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNB2004800039523A Expired - Lifetime CN100374422C (zh) 2003-02-12 2004-02-02 匹伐他汀钙的晶形
CN201110189197.4A Expired - Lifetime CN102285916B (zh) 2003-02-12 2004-02-02 匹伐他汀钙的晶形

Country Status (10)

Country Link
US (15) US20060142582A1 (https=)
EP (3) EP1592668A1 (https=)
JP (13) JP5192147B2 (https=)
CN (3) CN101219992B (https=)
AU (1) AU2004212160B2 (https=)
CA (2) CA2785954A1 (https=)
DE (1) DE202004021379U1 (https=)
PL (1) PL376557A1 (https=)
TW (4) TW201213311A (https=)
WO (1) WO2004072040A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101219992B (zh) * 2003-02-12 2011-08-31 日产化学工业株式会社 匹伐他汀钙的晶形
AU2013204129C1 (en) * 2003-12-26 2017-03-02 Nissan Chemical Industries, Ltd. Crystal Form of Quinoline Compound and Process for its Production
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
US20070173536A1 (en) * 2004-02-06 2007-07-26 Ciba Specialty Chemicals Holding Inc. Crystalline forms of zolmitriptan
WO2006079611A1 (en) * 2005-01-31 2006-08-03 Ciba Specialty Chemicals Holding Inc. Crystalline forms of rosuvastatin calcium salt
JP2013516459A (ja) 2010-01-20 2013-05-13 カディラ・ヘルスケア・リミテッド ピタバスタチン及び医薬として許容可能なそれらの塩の製造方法
JP2013536219A (ja) 2010-08-25 2013-09-19 カディラ・ヘルスケア・リミテッド ピタバスタチンカルシウムおよびその調製方法
EP3178812A1 (en) 2010-11-12 2017-06-14 Hetero Research Foundation Novel polymorphs of pitavastatin calcium
WO2012106584A2 (en) * 2011-02-04 2012-08-09 Dr. Reddy's Laboratories Ltd. Pitavastatin salts
ITMI20111475A1 (it) * 2011-08-02 2013-02-03 Dipharma Francis Srl Forme cristalline di pitavastatina sale di calcio
PT2751081T (pt) 2011-09-12 2017-04-04 D O O Farma Grs Forma polimórfica de pitavastatina cálcica
EP2768805B1 (en) * 2011-10-20 2020-03-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
WO2013098773A1 (en) * 2011-12-28 2013-07-04 Dr. Reddy's Laboratories Limited Crystalline forms of pitavastatin calcium
CN104860882A (zh) * 2015-05-15 2015-08-26 苗怡文 一种治疗高血脂症的药物匹伐他汀钙组合物
CN104844506A (zh) * 2015-05-15 2015-08-19 苗怡文 一种治疗高血脂症的药物匹伐他汀钙化合物
CN105125504A (zh) * 2015-09-17 2015-12-09 青岛华之草医药科技有限公司 一种降血脂药物匹伐他汀钙组合物颗粒剂
CN105213319A (zh) * 2015-09-17 2016-01-06 青岛华之草医药科技有限公司 一种降血脂药物匹伐他汀钙组合物干混悬剂
US10937978B2 (en) * 2016-02-25 2021-03-02 University Of Louisville Research Foundation, Inc. Methods for forming a perovskite solar cell
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
CN109053568A (zh) * 2018-08-29 2018-12-21 南京卓康医药科技有限公司 一种高纯度匹伐他汀钙新晶型及其制备方法
CN113834795B (zh) * 2020-06-08 2024-12-03 上海医药集团股份有限公司 硫酸羟氯喹颗粒水分近红外光谱在线定量模型及其建立方法及检测方法
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
EP4405360A4 (en) 2021-09-23 2025-08-20 Erasca Inc POLYMORPHIC FORMS OF EGFR INHIBITOR
CN116969884A (zh) * 2023-07-28 2023-10-31 河北广祥制药有限公司 一种匹伐他汀钙单晶及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011930A (en) * 1987-08-20 1991-04-30 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones
US5473075A (en) * 1991-06-24 1995-12-05 Nissan Chemical Industries Ltd. Diastereomer salt of optically active quinolinemevalonic acid
CN100374422C (zh) * 2003-02-12 2008-03-12 西巴特殊化学品控股有限公司 匹伐他汀钙的晶形

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3175944A (en) * 1956-06-18 1965-03-30 Upjohn Co Dihydronovobiocin and derivatives thereof
JPS61171460A (ja) 1985-01-23 1986-08-02 Dainippon Pharmaceut Co Ltd 塩酸メクロフエノキサ−ト１型結晶の製造法
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
EP0581552B1 (en) 1992-07-31 1998-04-22 Shionogi & Co., Ltd. Triazolylthiomethylthio cephalosporin hyrochloride, its crystalline hydrate and the production of the same
JP2575590B2 (ja) 1992-07-31 1997-01-29 塩野義製薬株式会社 トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
GB9324931D0 (en) * 1993-12-04 1994-01-26 Pfizer Ltd Glutaramide derivatives
EP0747341B1 (en) 1994-02-25 2002-05-22 Daicel Chemical Industries, Ltd. Process for producing optically active mevalonolactone compounds
JP3558684B2 (ja) 1994-06-28 2004-08-25 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の乾燥方法
JP4281248B2 (ja) * 1998-07-23 2009-06-17 日産化学工業株式会社 キノリン誘導体の製造法及び中間体
JP4749533B2 (ja) * 1999-09-30 2011-08-17 大塚化学株式会社 セファロスポリン結晶
AU2002212340B2 (en) * 2000-10-31 2006-12-14 Sandoz Ag Crystalline forms of venlafaxine hydrochloride
PL362981A1 (en) * 2000-11-16 2004-11-02 Teva Pharmaceutical Industries Ltd. Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
EP1345903A1 (en) * 2000-12-21 2003-09-24 Ciba SC Holding AG Crystalline forms of cerivastatin sodium
AU2002324715B2 (en) * 2001-08-16 2009-03-12 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
US6835838B2 (en) * 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
PL370658A1 (en) * 2002-01-31 2005-05-30 Novartis Ag Process for the manufacture of hmg-coa reductase inhibitors
GB0204129D0 (en) 2002-02-21 2002-04-10 Novartis Ag Process for the manufacture of organic compounds
AU2003231361A1 (en) 2002-04-17 2003-10-27 Yamanouchi Pharmaceutical Co., Ltd. Novel crystal of quinoxalinedione derivative anhydride
GB0210234D0 (en) 2002-05-03 2002-06-12 Novartis Ag Process for the manufacture of organic compounds
TWI328006B (en) 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
CN100344422C (zh) * 2006-05-11 2007-10-24 朱能国 用人工用材林松木及其板材生产阻燃防潮装饰板材的方法
JP5353678B2 (ja) * 2009-12-17 2013-11-27 トヨタ自動車株式会社 車両の制御装置

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011930A (en) * 1987-08-20 1991-04-30 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones
US5473075A (en) * 1991-06-24 1995-12-05 Nissan Chemical Industries Ltd. Diastereomer salt of optically active quinolinemevalonic acid
CN100374422C (zh) * 2003-02-12 2008-03-12 西巴特殊化学品控股有限公司 匹伐他汀钙的晶形

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Medicinal Chemistry Letters9.1999,92977-2982. *
Mikio Suzuki, et al..FIRST SYSTEMATIC CHIRAL SYNTHESES OF TWOPAIRS OF ENANTIOMERS WITH 3,5-DIHYDROXYHEPTENOIC ACID CHAIN, ASSOCIATEDWITH A POTENT SYNTHETIC STATIN NK-104.Bioorganic &amp *
MikioSuzuki et al..FIRST SYSTEMATIC CHIRAL SYNTHESES OF TWOPAIRS OF ENANTIOMERS WITH 3

Also Published As

Publication number Publication date
US20170022163A1 (en) 2017-01-26
JP5702494B2 (ja) 2015-04-15
EP1592668A1 (en) 2005-11-09
AU2004212160A1 (en) 2004-08-26
JP2014198743A (ja) 2014-10-23
WO2004072040A1 (en) 2004-08-26
US20120101126A1 (en) 2012-04-26
US20090182008A1 (en) 2009-07-16
JP2014205723A (ja) 2014-10-30
CN100374422C (zh) 2008-03-12
JP2018044009A (ja) 2018-03-22
TW200420541A (en) 2004-10-16
TW201345893A (zh) 2013-11-16
JP2019031574A (ja) 2019-02-28
US20060142582A1 (en) 2006-06-29
TW201213311A (en) 2012-04-01
US20140005402A1 (en) 2014-01-02
US20180346425A1 (en) 2018-12-06
TWI485135B (zh) 2015-05-21
DE202004021379U1 (de) 2008-02-21
US8853405B2 (en) 2014-10-07
EP3299359A1 (en) 2018-03-28
JP5500305B2 (ja) 2014-05-21
JP5445713B2 (ja) 2014-03-19
US20190256469A1 (en) 2019-08-22
US20160024010A1 (en) 2016-01-28
US20140364614A1 (en) 2014-12-11
JP2013177466A (ja) 2013-09-09
US20210002227A1 (en) 2021-01-07
JP2014055185A (ja) 2014-03-27
US8557993B2 (en) 2013-10-15
CN101219992A (zh) 2008-07-16
PL376557A1 (pl) 2006-01-09
US20130053413A1 (en) 2013-02-28
JP2014024848A (ja) 2014-02-06
TW201514149A (zh) 2015-04-16
JP5192147B2 (ja) 2013-05-08
JP2016222737A (ja) 2016-12-28
CN102285916A (zh) 2011-12-21
US20180029987A1 (en) 2018-02-01
JP2020169196A (ja) 2020-10-15
CN102285916B (zh) 2015-02-25
EP2500339A1 (en) 2012-09-19
JP2011201915A (ja) 2011-10-13
US20220169614A1 (en) 2022-06-02
CA2785954A1 (en) 2004-08-26
JP2006518354A (ja) 2006-08-10
JP2014062115A (ja) 2014-04-10
CN1747934A (zh) 2006-03-15
CA2513837A1 (en) 2004-08-26
JP5366163B2 (ja) 2013-12-11
JP2015172086A (ja) 2015-10-01
US20200148644A1 (en) 2020-05-14
US20230322680A1 (en) 2023-10-12
AU2004212160B2 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
CN101219992B (zh) 匹伐他汀钙的晶形
CA2426632C (en) Atorvastatin hemi-calcium form vii
CN105315266B (zh) 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的晶型
CN101437791A (zh) 储存后稳定的阿托伐他汀钙的结晶形式

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: NISSAN CHEMICAL IND LTD.

Free format text: FORMER OWNER: CIBA SPECIALTY CHEMICALS HOLDING INC.

Effective date: 20080829

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20080829

Address after: Tokyo, Japan

Applicant after: NISSAN CHEMICAL INDUSTRIES, Ltd.

Address before: Basel, Switzerland

Applicant before: Ciba Specialty Chemicals Holding Inc.

C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20110831

CX01 Expiry of patent term